Atnaujinkite slapukų nuostatas

El. knyga: Oxford Handbook of Practical Drug Therapy

4.56/5 (17 ratings by Goodreads)
(Clinical Director, GlaxoSmithKline Academic Discovery, UK), , (Clinical Reader in Clinical Pharmacology, Department of Clinical Pharmacology, University of Oxford, UK), (Consultant Physician and Clinical Pharmacologist, Oxford Radcliffe )
  • Formatas: EPUB+DRM
  • Serija: Oxford Medical Handbooks
  • Išleidimo metai: 10-Nov-2011
  • Leidėjas: Oxford University Press
  • Kalba: eng
  • ISBN-13: 9780191043673
Kitos knygos pagal šią temą:
  • Formatas: EPUB+DRM
  • Serija: Oxford Medical Handbooks
  • Išleidimo metai: 10-Nov-2011
  • Leidėjas: Oxford University Press
  • Kalba: eng
  • ISBN-13: 9780191043673
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Safe and effective prescribing is a cornerstone of proper patient care. There has in recent years been a significant increase in the numbers of healthcare professionals able to prescribe; however, sources of drug information tend to focus on only one area of prescribing. The Oxford Handbook of Practical Drug Therapy links practical information about how to use medicines with concise details about the pharmacology of a drug, and the principles of clinical pharmacology that govern its action.

The overall structure of this handbook is similar to the UK national formulary, with topics on each drug arranged broadly by therapeutic category. When a drug has several different uses, these are brought together in a single topic, allowing the reader to appreciate its full range of actions, whether therapeutic or adverse.
Each drugs topic provides information in a clearly laid out and standardised form, and includes a graphical representation of the pharmacological actions of the drug, and its potential uses, practical advice on a drug's major indications, a list of common and serious adverse effects, major drug-drug interactions, practical advice on monitoring for therapeutic and adverse effects, and what to tell the patient.

Teaching points throughout the text, draw out pharmacological principles, so that readers can increase their basic knowledge by linking theory with practical examples. Also included are several boxes giving guidance on the approach to therapy of specific diseases an clinical problems. In some cases, algorithms for the treatment of medical emergencies are given, and this new edition features case histories throughout the text to illustrate the issues one may face in practical prescribing.

The Oxford Handbook of Practical Drug Therapy brings together for the first time in a single book really practical information on safe prescribing, with the background knowledge that underpins clinical pharmacology. Fully revised with new guidance and important safety information, this book is aimed primarily at medical students and trainees, it will also be invaluable to family doctors, clinical pharmacists, and nurse prescribers.

Recenzijos

I would recommend the Oxford Handbook of Practical Drug Therapy for both use on the wards and for revision for medical school exams. . . Its in depth cover of relevant prescribing information will make it a useful resource for junior doctors as well as medical students. * Lucy Faulkner, Northwing Magazine Sheffield University Medical Students Magazine * This is a small compact and easy to utilise drug therapy manual. Overall a well set out easy to follow guide that would be useful for health professionals of all levels. * ANTS Bulletin *

Symbols and abbreviations xv
How to use this book xxi
Introductory sections 1(30)
Prescribing
The drug history
2(3)
Writing a prescription
5(1)
Generic drugs and biosimilars
6(1)
Repeat prescriptions
7(2)
Off-licence drugs Cautionary and advisory labels
9(1)
Some basic concepts
The World Health Organization (WHO) essential medicines list
10(1)
Compliance, adherence, and concordance
11(1)
Guidelines
12(2)
Dose-response curves (concentration-effect curves)
14(1)
Efficacy of drugs
15(1)
Adverse drug reactions
16(2)
Drug-drug interactions
18(2)
Placebos
20(1)
Changing the doses of drugs
21(1)
Renal insufficiency
22(1)
Hepatic insufficiency
22(1)
An approach to rational prescribing
23(1)
Paediatric prescribing
24(2)
Drugs and pregnancy
26(2)
Drug therapy and breastfeeding
28(2)
Drug development
30(1)
1 Gastrointestinal system 31(50)
Gastric acid suppression
Histamine H., receptor antagonists BNF 1.3.1
32(2)
Proton pump inhibitors (PPIs) BNF 1.3.5
34(4)
Misoprostol BNF 1.3.4, 10.1.1
38(4)
Drugs affecting gastrointestinal motility
Constipation BNF 1.6
42(2)
Co-phenotrope (Lomotil®) BNF 1.4.2
44(2)
Loperamide (Imodium®) BNF 1.4.2
46(2)
Inflammatory Bowel Disease
Mesalazine and related compounds (aminosalicylates) BNF 1.5
48(4)
Su ifasalazine BNF 1.5.1 and 10.13
52(2)
Liver, biliary system, and lipids
Cholic acids BNF 1.9.1
54(2)
HMG CoA reductase inhibitors ('statins') BNF 2.12
56(4)
Ezetirnibe BNF 2.12
60(2)
Fibrates BNF 2.12
62(2)
Obesity
Orlistat BNF 4.5.1
64(2)
Antiemetics
Metoclopramide BNF 4.6
66(4)
Prochlorperazine (Stemetir) BNF 4.6
70(6)
Domperidone BNF 4.6
76(2)
Serotonin 5-HT3 receptor antagonists BNF 4.6
78(3)
2 Cardiovascular system 81(160)
A pharmacological approach to the treatment of arrhythrnias BNF 2.3.1
84(2)
Antiarrhythmic drugs
Adenosine BNF 2.3.2
86(4)
Flecainide BNF 2.3.2
90(4)
Cardiac glycosides (digitalis) BNF 2.1.1, 2.3.1. and 2.5.5
94(6)
Disopyramide BNF 2.3.2
100(4)
Amiodarone BNF 2,3.2 and 2.7.3
104(6)
Anticoagulants, antiplatelet drugs, and fibrinolytic drugs
Heparins (unfractionated and low molecular weight) BNF 2.8.1
110(8)
Direct thrombin inhibitors BNF 2.8.2
118(2)
Fondaparinux sodium BNF 2.8.1
120(4)
Warfarin BNF 2.8.2
124(8)
Acetylsalicylic acid (aspirin) BNF 2.9 and 4.7.1
132(6)
Clopidogrel BNF 2.9
138(4)
Dipyridamole BNF 2.9
142(2)
Glycoprotein Ilbillia antagonists BNF 2.9
144(2)
Fibrinolytic drugs BNF 2.10.2 and 13.11.7
146(4)
Ischaemic Heart Disease
Pharmacology of drugs used to treat acute coronary syndromes, including myocardial infarction BNF 2.10
150(1)
Pharmacology of drugs used to treat heart failure
151(1)
Nitrate drugs BNF 2.6.1
152(4)
Nicorandil BNF 2.6.3
156(2)
Beta-adrenoceptor antagonists ('beta-blockers') BNF 2.4, 2.5.5, 6.2.2, 4.7.4, 11.6
158(8)
Angiotensin converting enzyme inhibitors (ACE inhibitors) BNF 2.5.5.1
166(6)
Angiotensin receptor antagonistsiblockers (ARBs) BNF 2.5.5.2
172(4)
Hypertension
An approach to the treatment of hypertension BNF 2.5
176(2)
Methyldopa (alpha-methyldopa) BNF 2.5.2
178(2)
Calcium channel blockers
Calcium channel blockers (see also individual sections) BNF 2.6.2
180(2)
Dihydropyridines (nifedipine-like) BNF 2.6.2
182(4)
Benzothiazepines (diltiazem) BNF 2.6.2 and 2.3.2
186(2)
Phenylalkylamines (verapamil) BNF 2.6.2 and 2.3.2
188(2)
Intravenous Fluids
Crystalloid solutions for intravenous infusion BNF 9.7
190(4)
Colloid solutions for intravenous infusion BNF 9.2
194(3)
Diuretics
Sites of action of diuretics BNF 2.2
197(1)
Treatment of pulmonary oedema BNF 2.2
198(2)
Loop diuretics BNF 2.2.2 and 2.2.4
200(6)
Thiazide and thiazide-like diuretics BNF 2.7.1, 2.5.5, and 6.5.2
206(4)
Potassium-sparing diuretics (amiloride and triamterene) BNF 2,2.3 and 2.2.4
210(4)
Spironolactone and eplerenone BNF 2.2.3, 2.2.4, and 2.5.5
214(4)
Adrenoceptor agonists
Adrenoceptor agonists (sympathomimetics) BNF 2.7
218(8)
Antimuscarinic drugs
Muscarinic acetylcholine receptor antagonists (atropine and related compounds) BNF 35.1.3, 4.6, 4.9.2, 7.4.2, and 11.5
226(6)
Endothelin receptor antagonists
Endothelin receptor antagonists BNF 2.5.1
232(4)
Drugs for erectile dysfunction
Phosphodiesterase type V inhibitors BNF 7.4.5
236(5)
3 Respiratory system 241(38)
Oxygen
Oxygen BNF 3.6
242(4)
Asthma and chronic obstructive pulmonary disease (COPD)
Pharmacology of drugs used to treat asthma BNF 3.1
246(2)
An approach to the treatment of chronic obstructive pulmonary disease (COPD) BNF 3.2
248(2)
Short-acting 132 adrenoceptor agonists BNF 3.1.1.1 and 7.1.3
250(4)
Long-acting 132 adrenoceptor agonists BNF 3.1.1.1
254(4)
Bronchodilatory muscarinic receptor antagonists BNF 3.1.2
258(4)
Leukotriene receptor antagonists BNF 3.3.2
262(2)
Cromones BNF 3.3.1.1.5, and 11.4.2
264(2)
Xanthine derivatives BNF,3.1.3
266(6)
Respiratory stimulants
Doxaprarn BNF 3.5.1
272(2)
Smoking cessation
Nicotine BNF 4.10
274(2)
Bupropion (amfebutamone) BNF 4.10
276(3)
4 Central nervous system 279(94)
Anticonvu Isants
Carbamazepine BNF 4.8.1, 4.7.3, 6.5.2, 6.1.5
280(8)
Phenytoin BNF 4.8.1, 4.8.2 and 4.7.3
288(6)
Sodium valproate BNF 4.8.1
294(4)
Lamotrigine BNF 4.8.1
298(4)
Other antiepileptic drugs BNF 4.8.1
302(2)
Barbiturates BNF 4.1.3. 4.8.1 and 15.1.1
304(4)
Anxiolytics and hypnotics
Benzediazepines BNF 4.1.1, 4.1.2 and 4.8.2
308(8)
Renzodiazepine-like hypnotics BNF 4.1.1
316(2)
Depression
Tricyclic antidepressants BNF 4.3.1, 6.1.5, 4.7.4.2 and 7.4.2
318(6)
Selective serotonin reuptake inhibitors (SSRIs) BNF 4.3.3
324(6)
Venlafaxine BNF 4.3.4
330(2)
Monoamine oxidase inhibitors (MAOIs) ar4F 4.3.2, 4.9.1
332(4)
Psychoses and bipolar disorder
Antipsychatic/neuroleptic drugs BNF 4,2
336(6)
Atypical antipsychotic drugs BNF 4.2.1
342(6)
Lithium BNF 4.2.3
348(4)
Parkinson's disease
Pharmacology of drugs used to treat Parkinson's disease BNF 4.9
352(2)
Levodopa (L-dopa) BNF 4.9.1
354(4)
Dopamine receptor agonists BNF 4.9.1 and 6.7.1
358(4)
Entacapone BNF 4.9.1 and 6.7.1
362(2)
Anticholinesterases
Acetylcholinesterase inhibitors BNF 10.2.1, 4.11, 15.1.6, 7.4,1 and 1.6.2
364(4)
Migraine
Serotonin 5-HT1 receptor agonists ('triptans') BNF 4.7.4
368(5)
5 Infections 373(78)
Antibacterial drugs
Penicillins BNF 5.1.1
374(4)
Carbapenems BNF 5.1.2
378(2)
Cephalosporins and cephamycins BNF 5.1.2
380(4)
Glycopeptide antibiotics BNF 5.1.7
384(4)
Tetracyclines BNF 5.1.3 and 13.6.2
388(6)
Aminoglycoside antibiotics BNF 5.1.4
394(4)
Macrolide antibiotics BNF 5.1.5
398(6)
Sulfonamides and trimethoprim (including co-trimoxazole) BNF 5.12 and 13.10.1.1
404(6)
Metronidazole and tinidazole BNF 5.1.11
410(4)
Quinolone antibiotics BNF 5.1.12
414(4)
Antituberculosis drugs
Antituberculosis drugs BNF 5.1.9
418(4)
Antiviral drugs
Antiviral guanine derivatives BNF 5.3, 11.3.3, and 13.10.3
422(6)
Drugs used to treat human immunodeficiency virus (HIV) infection BNF 5.3
428(8)
Antifungal drugs
Imidazole and triazole antifungal drugs BNF 5.2, 7.2.2, 12.3.2, and 13.10.2
436(4)
Polyene antifungal drugs BNF 5.2, 7.2.2, 12.3.2, and 13.10.2
440(4)
Antimalarial drugs
Antimalarial drugs BNF 5.4.1
444(7)
6 Endocrine system; obstetrics and gynaecology 451(84)
Diabetes mellitus
Insulin BNF 6.1.1
452(10)
Glucagon BNF 6.1.4
462(2)
Sulfonylureas BNF 6.1.2,1
464(4)
Meglitinides BNF 6.1.2.3
468(2)
Biguanides (metformin) BNF 6.1.2.2
470(4)
Thiazolidinediones ('glitazones') BNF 6.1,2,3
474(4)
Thyroid disease
Thyroid hormones BNF 6.2.1
478(4)
Carbirnazole BNF 6.2.2
482(4)
Corticosteroids
Corticosteroids BNF 6.3
486(2)
Glucocorticoids BNF 6.3
488(8)
Corticotrophins
Corticotrophins BNF 6.5.1
496(2)
Sex steroids
Oestrogens and hormone replacement therapy (HRT) BNF 6.4.1, 7.2.1 and 8.3.1
498(4)
Progestogens BNF 6.4.1.2, 8.3.2, and 7.3
502(2)
Oral contraceptives BNF 7.3
504(4)
Notes on contraceptive devices BNF 7.3.2.3, 7.3.3, and 7.14
508(2)
Gonadorelln analogues BNF 6.7.2 and 8.3.4.1 & 2
510(2)
Androgens and anabolic steroids BNF 6.4,2 and 6.4.3
512(4)
Antiandrogens BNF 8.3.4.2, 6.4,2 and 13.6.2
516(4)
Selective oestrogen receptor modulators (SERMs) BNF 8.3.4.1 and 6.5.1
520(4)
Aromatase inhibitors BNF 8.3.4.1
524(2)
Obstetrics
Prostaglandins BNF 7.1.1,7.4.5, and 11.6
526(4)
Oxytocin BNF 7.1.1
530(2)
Somatostatin and analogues
Somatostatin and analogues BNF 8.3.4.3
532(3)
7 Kidneys and the urinary tract 535(18)
Drugs and the kidneys
Renal insufficiency BNF 7.4.3
536(2)
Drug-induced renal damage BNF 7.4,3
538(2)
Drugs and renal stones BNF 7.43
540(2)
Drugs and renal replacement therapy (dialysis or filtration) BNF 7.4,3
542(2)
Drugs used in the management of chronic renal insufficiency BNF 7.4.3
544(2)
Urinary tract
Alpha-adrenoceptor antagonists (alpha-blockers) BNF 7.4.1 and 2.5.4
546(4)
Antidiuretic hormone (ADH, vasopressin) and analogues SNF 7.4.1 and 7.4.2
550(3)
8 Malignant disease and immunosuppression 553(44)
Drugs used to treat cancer
Drugs used to treat cancer BNF 8.1
554(2)
Adverse effects of cytotoxic chemotherapy BNF 8.1
556(2)
Chlorambucil BNF 8.1.1
558(2)
Cyclophosphamide BNF 8.1.1
560(2)
Cytotoxic antibiotics BNF 8.1.2
562(4)
Antimetabolite drugs BNF 8.1.3, 10.1.3, and 13.5.2
566(4)
Methotrexate BNF 8:1.3, 10.1.3, and 13.5.2
570(4)
Vinca alkaloids BNF 8.1.4
574(2)
Platinum compounds BNF 8.1.5
576(2)
Taxanes BNF 8.1.5
578(2)
Cytotoxic monoclonal antibodies BNF 8.1.5 and 8.2.3
580(4)
Immunosuppression
Azathioprine and mercaptopurine BNF 8.2, 8.1.3, 1.5. 10.1.3, and 10.2.1
584(4)
Mycophenolate mofetit and mycophenolic acid BNF 8.2.1
588(4)
Ciclosporin, tacrolimus, and sirolimus BNF 8.2.2 and 13.5.3
592(5)
9 Nutrition and blood 597(42)
Blood, blood products, and anaemia
Drugs and anaemia BNF 9.1
598(2)
Blood transfusion
600(4)
Factor VIII and related products BNF 2.11
604(4)
Erythropoietin and analogues BNF 9.1.3
608(4)
Colony stimulating factors BNF 9.1.6
612(2)
Iron salts BNF 9.1.1
614(4)
Folic acid and folinic acid BNF 9.1.2 and 8.1
618(2)
Vitamin Bit taNF 9.1.2
620(2)
Desferrioxamine (deferoxamine) BNF 9.1.3
622(2)
Minerals
Calcium salts ONE 9.5.1.1 and 9.6.4
624(2)
Magnesium sulphate BNF 9.5.1.3
626(2)
Potassium chloride BNF 9.2.1.1
628(4)
Vitamins
Vitamin D analogues ONE 9.6.4 and 13.5.2
632(4)
Vitamin K1 ONE 9.6.6
636(3)
10 Musculoskeletal and joints 639(38)
Gout
Coichicine ONE 10.1.4
640(2)
Allopurinol ONE 10.1.4 and 8.1
642(2)
Rheumatoid arthritis (disease-modifying drugs)
Rheumatoid arthritis (disease-modifying drugs) BNF 10.1
644(2)
Chloroquine and hydroxychloroquine BNF 5.4.1 and 10.1.3
646(4)
Gold salts BNF 10.1.3
650(2)
Leflunomide BNF 10.1.3
652(2)
Tumour necrosis factor (TNF) blocking drugs BNF 10.1.3 and 1.5.3
654(4)
Osteoporosis
Calcitonin BNF 6.6.1 and 9.5.1.2
658(2)
Bisphosphonates BNF 6.6.2 and 9.5.1.2
660(6)
Drugs affecting muscle
Baciofen BNF 10.2.2
666(2)
Dantrolene BNF 15.1.8 and 10.2.2
668(2)
Neuromuscular blocking drugs BNF 15.1.5
670(4)
Botulinum toxin BNF 4.9.3
674(3)
11 Eye 677(10)
Glaucoma
Acetylcholine receptor agonists BNF 11.6, 12.3.5, and 7.4.1
678(2)
Carbonic anhydrase inhibitors BNF 11.6, 4.8, and 2.2.7
680(4)
Drugs for macular degeneration BNF 11.8.2
684(3)
12 Skin 687(8)
Antihistamines
Antihistamines BNF 3.4.1, 13.5.1, 11.4.2, 4.6, and 12.2.1
688(4)
Retinoids
Retinoids BNF 13.6.1, 8.15, 13.5.2 and 13.8.1
692(3)
13 Poisoning 695(24)
Treatment of poisoning
An approach to the poisoned patient
696(2)
Activated charcoal
698(2)
Antidotes
Acetylcysteine (Parvolex)
700(4)
Opioid antagonists BNF 15.1.7
704(6)
Flumazenil BNF 15.1.7
710(2)
Penicillamine BNF 9.8.1 and 10.1.3
712(4)
Diagnostic agents
Diagnostic agents
716(3)
14 Immunological products and vaccines 719(16)
Immunoglobutins
Immunoglobulins BNF 14.5 and 14.2
720(4)
Interferons
Interferons BNF 8.2.4, 5.3, and 14.5
724(4)
Vaccines
Vaccines BNF 14.1
728(4)
UK immunization schedule BNF 14.1 and 14.4
732(3)
15 Relief of pain and anaesthetic drugs 735(44)
Analgesics
Palliative care
736(2)
Paracetamol (acetaminophen) BNF 4.7.1
738(4)
Non-steroidal anti-inflammatory drugs (NSAIDS) BNF 10.1.1 and 15.1.4.2
742(6)
Codeine phosphate and dihydrocodeine BNF 4.7.1, 4.7.2, 1.4.2 and 3.9.1
748(4)
Opiates and non-opiate narcotic analgesics BNF 4.7.2 and 15,1.4.3
752(8)
Treatment of neuropathic pain BNF 4.7.3.
760(2)
Pregabalin BNF 4.7.3 and 4.8.1
762(2)
Gabapentin BNF 4.7.3, 4.8.1 and 6.1.5
764(2)
Capsaicin BNF 10.3.2, 4.7.3, and 6.1.5
766(2)
Lidocaine (lignocaine) BNF 2.3.2 and 15.2
768(4)
Prepofol BNF 15.4.1
772(4)
Volatile anaesthetics BNF 15.1.2
776(3)
Drug index 779(10)
Subject index 789
Duncan Richards trained in clinical pharmacology at Oxford where he developed a strong interest in translational pharmacology. Since completing his training, Duncan has worked in drug discovery for GSK. His current role is as Clinical Director of the Academic Discovery Performance Unit. This group aims to bring together the drug development expertise of GSK with the specialist knowledge of academic investigators to develop a portfolio of novel drug molecules.

Jeff Aronson is Reader in Clinical Pharmacology, University of Oxford, and Honorary Consultant Physician to the Oxford Radcliffe Hospitals NHS Trust. He does acute medical takes and teaches clinical students general medicine and practical drug therapy and prescribing. His research interests span all aspects of clinical pharmacology, especially adverse drug reactions and monitoring therapeutic interventions. He is President of the British Pharmacological Society, a member of the Formulary Committees of the British National Formulary and the British National Formulary for Children, a member of the Technology Appraisal Committee of NICE, Chairman of the British Pharmacopoeia Commission's Expert Advisory Group on Nomenclature, and Editor-in-Chief of Meyler's Side Effects of Drugs-The International Encyclopedia of Adverse Drug Reactions and Interactions (15th edition, 2006) and of its annual update volumes (Side Effects of Drugs Annuals). For a full curriculum vitae, see www.clinpharm.ox.ac.uk/JKA.



Dr Jamie Coleman received his MBChB from the University of Birmingham in 1999. He trained in the West Midlands as a Clinical Pharmacologist undertaking an MD on the subject of adverse drug reactions which he completed in 2008. During his training he also developed an interest in medical teaching and gained an MA Medical Education in 2008. He took up a Consultant Clinical Pharmacologist job in early 2009 at the University Hospitals Birmingham NHS Foundation Trust and is an honorary senior lecturer in the College of Medical and Dental Sciences at the University of Birmingham. He continues to be involved in the teaching of therapeutics and prescribing to a wide variety of healthcare professionals at both undergraduate and postgraduate levels.